Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





AstraZeneca's COVID-19 Vaccine Is World’s Leading Candidate and May Deliver Results Earlier, Says WHO

By HospiMedica International staff writers
Posted on 29 Jun 2020
The experimental COVID-19 vaccine from AstraZeneca (Cambridgeshire, England) is possibly the world’s leading candidate and the most advanced in terms of development, according to the chief scientist of the World Health Organization (WHO).

“Certainly in terms of how advanced they are, the stage at which they are, they are I think probably the leading candidate,” WHO chief scientist Soumya Swaminathan told a news conference. More...
“So it’s possible they will have results quite early.”

A report by Reuters has stated that AstraZeneca had already commenced large-scale, mid-stage human trials of the vaccine developed by researchers at University of Oxford and recently signed its 10th supply-and-manufacturing deal. According to Swaminathan, Moderna’s COVID-19 vaccine candidate was “not far behind” that of AstraZeneca and among more than 200 candidates, 15 had entered clinical trials.

“We do know that Moderna’s vaccine is also going to go into phase three clinical trials, probably from the middle of July, and so that vaccine candidate is not far behind,” said Swaminathan. “But I think AstraZeneca certainly has a more global scope at the moment in terms of where they are doing and planning their vaccine trials.”

Swaminathan said that the WHO was in discussions with several Chinese manufacturers, including Sinovac, as well as with Indian researchers on potential vaccines and called for drugmakers to consider collaborating on COVID-19 vaccine trials.




Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Adjustable Mobile Barrier
M-458
Mobile X-Ray System
K4W
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.